Lv2
128 积分 2024-07-31 加入
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
14天前
已完结
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease†
24天前
已完结
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
1个月前
已完结
The protective effect of PNU-282987, a selective α7 nicotinic acetylcholine receptor agonist, on the hepatic ischemia-reperfusion injury is associated with the inhibition of high-mobility group box 1 protein expression and nuclear factor κB activation in mice
1个月前
已完结
Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis
1个月前
已完结
Signaling inflammation across the gut-brain axis
3个月前
已完结
The gut vascular barrier: a new player in the gut–liver–brain axis
3个月前
已完结
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach
4个月前
已完结
The liver–brain axis in metabolic dysfunction-associated steatotic liver disease
4个月前
已完结
Type 3 cytokines IL-17A and IL-22 drive TGF-β–dependent liver fibrosis
4个月前
已完结
皖公网安备34019202002308
